Sera Prognostics Inc. 是母胎健康領域的先驅,專注於旨在改善妊娠結果的前沿診斷解決方案。其旗艦產品 PreTRM 檢測利用獨特的生物標誌物平台,準確評估早產風險,使醫療保健提供者能夠及時實施有影響力的干預措施。憑藉對推進產前診斷和應對關鍵健康挑戰的堅定承諾,Sera 在孕產婦健康領域處於戰略有利地位,可實現顯著增長,為投資者提供創造長期價值的誘人機會。
財務指標
營業收入
2026-09-30
$42K
2026-06-30
$30K
2026-03-31
$14K
2025-12-31
$10K
營業支出
2026-09-30
$8.86M
2026-06-30
$9.98M
2026-03-31
$9.33M
2025-12-31
$8.92M
淨利潤
2026-09-30
-$8.05M
2026-06-30
-$9.13M
2026-03-31
-$8.39M
2025-12-31
-$7.88M
淨利潤率
2026-09-30
-19.17K%
2026-06-30
-30.46K%
2026-03-31
-59.99K%
2025-12-31
-78.81K%
每股收益
2026-09-30
$-0.16
2026-06-30
$-0.18
2026-03-31
$-0.17
2025-12-31
$-0.16
息稅折舊攤銷前利潤
2026-09-30
-$7.85M
2026-06-30
-$8.94M
2026-03-31
-$8.2M
2025-12-31
-$7.63M
有效稅率
2026-09-30
--
2026-06-30
--
2026-03-31
--
2025-12-31
--
項目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
營業收入
$42K
$30K
$14K
$10K
營業支出
$8.86M
$9.98M
$9.33M
$8.92M
淨利潤
-$8.05M
-$9.13M
-$8.39M
-$7.88M
淨利潤率
-19.17K%
-30.46K%
-59.99K%
-78.81K%
每股收益
$-0.16
$-0.18
$-0.17
$-0.16
息稅折舊攤銷前利潤
-$7.85M
-$8.94M
-$8.2M
-$7.63M
有效稅率
--
--
--
--
常見問題
SERA represents the publicly traded company Sera Prognostics, Inc., a women's health diagnostics company focused on developing and commercializing biomarker-based tests. Its primary offerings are intended to help predict the risk of preterm birth and other pregnancy complications, enabling clinicians to make more informed care decisions. The company combines proteomics and bioinformatics to identify molecular signatures associated with adverse pregnancy outcomes.
The latest price for SERA is shown at the top of this stock detail page and updates during market hours. Because stock prices change continuously with trading activity, any figure quoted here would quickly become outdated. For the most accurate and current price, please refer to the live quote displayed on this page.
Volatility for SERA can be gauged by examining its historical price swings, average daily trading volume, and the width of its 52-week range, all of which are available on this page. Shares of smaller healthcare diagnostics companies often experience larger percentage moves than broad market indices, especially around clinical data releases, regulatory news, or earnings reports. Reviewing recent price history can help investors understand the typical magnitude of SERA's daily and monthly fluctuations.
Since SERA may not yet be consistently profitable, traditional earnings-based metrics like the P/E ratio might not provide a complete picture. Investors often turn to enterprise value relative to revenue, price-to-sales, price-to-book, and comparisons with peers in the diagnostics sector. Reviewing the company's cash position, revenue trajectory, and pipeline progress alongside valuation multiples can help frame whether the current market price appears reasonable relative to its financial fundamentals and growth prospects.
To buy SERA, open a brokerage account that offers access to U.S. stock exchanges and search for the ticker SERA. You can then place a market or limit order during regular trading hours. Fractional shares may be available through some brokers, allowing you to invest a smaller dollar amount. Before trading, confirm any commissions, fees, and order types, and ensure your account is funded and cleared for equity trades.
Key risks for SERA include clinical, regulatory, and reimbursement uncertainties common to diagnostics companies. If its tests fail to gain broad adoption, receive unfavorable coverage decisions, or face competition, revenue may fall short of expectations. As a smaller-cap company, SERA may also have limited financial resources, potential dilution risk, and greater stock price volatility. Additionally, dependence on key partnerships or hospital systems could affect commercial success and financial stability.